Hashimoto's thyroiditis

What it is

Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient countries, affecting roughly 5% of adults and occurring 7–10 times more often in women than men. Also called chronic lymphocytic thyroiditis or Hashimoto's disease, it is the most prevalent autoimmune thyroid condition worldwide. The immune system mistakenly targets the thyroid gland — a butterfly-shaped structure at the base of the neck — causing chronic inflammation that progressively destroys hormone-producing tissue. As thyroid cells are lost, production of thyroxine (T4) and triiodothyronine (T3) declines, the pituitary responds by raising TSH, and overt hypothyroidism eventually develops in most cases.

The condition typically presents between ages 30 and 50, though it can appear at any age. It clusters in families and is associated with other autoimmune conditions including type 1 diabetes, rheumatoid arthritis, and lupus. In Canada, hypothyroidism — most often caused by Hashimoto's — is one of the most frequently managed endocrine conditions in primary care, and TSH testing is available through provincial laboratory networks including LifeLabs and Dynacare. The condition is lifelong but responds well to treatment.

Causes and mechanism

Hashimoto's arises from a combination of genetic susceptibility and environmental triggers. Two immune processes drive thyroid damage:

1. Autoantibody production — the immune system generates antibodies against thyroid peroxidase (TPO-Ab) and thyroglobulin (TG-Ab). TPO-Ab are detectable in approximately 90% of confirmed cases and are the primary serological marker used in diagnosis. These antibodies both signal and contribute to ongoing inflammation.
2. T-lymphocyte infiltration — immune cells accumulate within the thyroid, causing the chronic lymphocytic inflammation that gives the condition its histological name and progressively destroys thyroid follicles.

Several factors raise individual risk:

Risk factor	Evidence strength
Female sex (estrogen-immune interaction)	Strong
First-degree relative with autoimmune thyroid disease	Strong
HLA gene variants (e.g., HLA-DR3, HLA-DR5)	Moderate
Selenium deficiency	Moderate
Excessive iodine intake	Moderate
Postpartum period, significant stress, or viral illness	Moderate
Concurrent autoimmune condition (T1D, RA, lupus)	Moderate

The postpartum period deserves particular note: postpartum thyroiditis, which shares immune mechanisms with Hashimoto's, affects an estimated 5–10% of Canadian women in the year after delivery and can be an early presentation of underlying Hashimoto's disease.

Symptoms and diagnosis

Hashimoto's follows a variable course. Early on, some people experience a transient phase of hyperthyroid symptoms — palpitations, anxiety, weight loss, and sweating — called Hashitoxicosis, caused by stored hormone leaking from inflamed tissue. This phase is self-limiting and distinct from Graves' disease. As the gland loses function, hypothyroid symptoms emerge:

• Persistent fatigue and sluggishness
• Unexplained weight gain
• Cold intolerance
• Dry skin, brittle nails, hair thinning or loss
• Constipation and slowed heart rate
• Low mood, brain fog, difficulty concentrating
• Muscle aches and stiffness
• Heavy or irregular menstrual periods
• Facial or peripheral puffiness (myxoedema in severe cases)
• Goitre (visible or palpable thyroid enlargement, present in some cases)

Diagnostic workup typically includes:

1. TSH — the primary screening test; elevated TSH indicates underperformance of the thyroid
2. Free T4 — low or low-normal levels confirm hypothyroidism
3. TPO-Ab — positive in ~90% of Hashimoto's cases; confirms autoimmune origin
4. TG-Ab — useful when TPO-Ab is negative
5. Thyroid ultrasound — shows heterogeneous, reduced-echogenicity tissue consistent with lymphocytic infiltration; not required for diagnosis but often ordered when a goitre is present

In Canada, TSH and free T4 are covered under provincial health plans as standard laboratory tests. TPO antibody testing is also publicly covered in most provinces when ordered by a physician.

Treatment options

There is currently no therapy that reverses the underlying autoimmune process. Treatment targets the consequence — hypothyroidism — and is highly effective.

Levothyroxine (synthetic T4) is the standard first-line treatment once hypothyroidism is confirmed. It is taken once daily, ideally on an empty stomach at the same time each day. Dosing is individualized based on TSH, symptoms, age, and weight, and is adjusted at 6–10 week intervals until stable. Most people require lifelong therapy. Levothyroxine is covered under most provincial drug benefit programs in Canada, including Ontario's ODB and BC PharmaCare, typically at low or no cost for eligible patients.

Combination T4/T3 therapy — adding liothyronine (T3) or switching to desiccated thyroid extract (DTE, which contains both T4 and T3) — is considered for the minority of patients who remain symptomatic despite TSH normalization on levothyroxine alone. Evidence for this approach is mixed, and it is not universally recommended; the decision should be made with an endocrinologist.

Watchful waiting is appropriate when antibodies are positive but thyroid function remains normal (subclinical stage). Annual TSH monitoring is standard practice in this group, as not all will progress to overt hypothyroidism.

Nutritional considerations: Selenium supplementation (typically 200 mcg/day) has evidence supporting a reduction in TPO antibody levels and may protect thyroid tissue from oxidative damage, though it has not been shown to prevent progression to hypothyroidism. Iodine intake should be moderate — neither deficiency nor excess is beneficial. A gluten-free diet may reduce antibody levels in the subset of Hashimoto's patients who also have coeliac disease, but evidence does not support it as a general recommendation.

When to see a clinician in Canada

Seek assessment from a family physician or nurse practitioner if you have persistent, unexplained fatigue, weight gain, cold intolerance, hair thinning, low mood, cognitive difficulties, heavy periods, or a visible swelling at the front of the neck. These symptoms overlap with many conditions, so a blood test — not self-diagnosis — is the appropriate first step.

Referral to an endocrinologist is warranted if TSH remains difficult to normalize, symptoms persist despite adequate levothyroxine, combination therapy is being considered, or Hashimoto's is diagnosed during pregnancy or in the preconception period.

Canadians without a family physician can access thyroid assessment through virtual care platforms such as Maple, Felix, Cleo, or Phoenix, several of which can order provincial lab requisitions and follow up on results. Walk-in clinics and provincial telehealth lines (e.g., Health811 in Ontario) are also options for initial evaluation.

Limitations and open questions

Research is still emerging on several aspects of Hashimoto's management. The benefit of combination T4/T3 therapy over levothyroxine monotherapy remains contested — randomized trial results are inconsistent, and neither the American Thyroid Association nor the SOGC has issued a definitive recommendation for routine combination use. The role of selenium supplementation in slowing disease progression (as opposed to reducing antibody titres) is not yet established. Evidence on dietary interventions — including gluten-free diets in the absence of coeliac disease — is preliminary and based largely on small observational studies. The threshold TSH at which to initiate treatment in subclinical hypothyroidism, particularly in older adults, is an area of active debate. Health Canada has not issued specific guidance on Hashimoto's management separate from general hypothyroidism treatment frameworks. Patients should discuss individualized targets with their clinician rather than relying on population-level TSH reference ranges alone.